KLP Kapitalforvaltning AS Purchases 800 Shares of Natera, Inc. $NTRA

KLP Kapitalforvaltning AS grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 1.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,400 shares of the medical research company’s stock after acquiring an additional 800 shares during the period. KLP Kapitalforvaltning AS’s holdings in Natera were worth $7,501,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD raised its stake in Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after buying an additional 3,795,315 shares in the last quarter. Nuveen LLC bought a new position in Natera in the first quarter worth about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Natera by 140.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock worth $177,298,000 after buying an additional 732,156 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Natera by 9.9% in the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after buying an additional 660,538 shares in the last quarter. Finally, Ninety One UK Ltd raised its stake in Natera by 149.1% in the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after buying an additional 336,985 shares in the last quarter. 99.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 14,083 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $160.00, for a total value of $2,253,280.00. Following the sale, the chief executive officer owned 154,072 shares in the company, valued at approximately $24,651,520. This trade represents a 8.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Fesko sold 678 shares of the firm’s stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $155.46, for a total transaction of $105,401.88. Following the completion of the sale, the insider owned 152,747 shares in the company, valued at $23,746,048.62. This represents a 0.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,464 shares of company stock valued at $10,963,125 in the last ninety days. Corporate insiders own 5.63% of the company’s stock.

Natera Stock Up 0.6%

NASDAQ:NTRA opened at $173.05 on Friday. The company’s 50 day moving average price is $163.88 and its 200-day moving average price is $157.12. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00. The stock has a market cap of $23.75 billion, a price-to-earnings ratio of -90.60 and a beta of 1.74.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The firm had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter in the previous year, the company earned ($0.30) EPS. The company’s quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Morgan Stanley reissued an “overweight” rating and issued a $195.00 price target on shares of Natera in a research note on Sunday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Wednesday. Stephens restated an “overweight” rating and issued a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Piper Sandler restated an “overweight” rating and issued a $220.00 price objective (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Barclays restated an “overweight” rating and issued a $210.00 price objective (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.